Graduated in Medicine from the University of São Paulo (1981), master's degree in Medicine from the University of São Paulo (1986), PhD in Medicine from the University of São Paulo (1993) and professorship from the same University in 1999. He is currently a full professor at the Faculty of Medicine of Ribeirão Preto of the University of São Paulo, , Coordinator of the Cell Therapy Center (CTC-CEPID-FAPESP) and Coordinator of the National Institute of Science and Technology in Stem Cells and Cellular Therapy (INCTC), (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The Nucleus of Cellular Therapy - NuTeC will be founded on the union of the Regional Blood Center of Ribeirão Preto (Hemocentro RP) and Butantan. Hemocentro RP expertise in cellular therapy will be added to Butantan excellence in the development and production of health applied products to develop CAR T cell therapy. The activities to be conducted by NuTeC are aligned with the scope of th…
The Regional Blood Center of Ribeirão Preto is a health care, education, and research organ linked to the Ribeirão Preto Medical School. It hosts the CTC- Center for Cell-based Therapy - CEPID - FAPESP and INCTC - National Institute of Science and Technology on Stem Cells and Cell Therapy CNPQ/FAPESP. The Regional Blood Center has 11.804 m2 of constructed area, of which 5.217 m2 are desig…
The present proposal establishes the continuity and expansion of the activities of the National Institute of Science and Technology in Stem Cells and Cell Therapy, one of the National Institutes of Science and Technology created by CNPq/FAPESP in 2008. In that opportunity, we proposed the development of an extensive program of basic and clinical research to understand, isolate, culture an…
(Only some records are available in English at this moment)
The Regional Blood Center of Ribeirão Preto is a health care, education, and research organ linked to the Ribeirão Preto Medical School. It hosts the CTC- Center for Cell-based Therapy - CEPID - FAPESP and INCTC - National Institute of Science and Technology on Stem Cells and Cell Therapy CNPQ/FAPESP. The Regional Blood Center has 11.804 m2 of constructed area, of which 5.217 m2 are desi…
After months of the worldwide spread of the SARS-CoV-2 novel coronavirus, it has become clear that the development and manufacturing of a safe and effective vaccine is a promising public policy strategy to combat the pandemic that will allow for the complete reopening of the economy and the prevention of new epidemic waves. Instituto Butantan is a century-old institution dedicated to the …
The Regional Blood Center of Ribeirão Preto is a center of medical care, education and research linked to the School of Medicine of Ribeirão Preto. It holds the CTC- Center for Cell-based Therapy- CEPID-FAPESP and INCTC - National Institute of Science and Technology in Stem Cell and Cell Therapy in Cancer - CNPq/FAPESP. The Hemocentro Foundation of Ribeirão Preto has independent administr…
(Only some records are available in English at this moment)
The cancer immunotherapies have shown promising results compared to the conventional therapies, such as the adoptive therapy of T lymphocytes expressing chimeric antigen receptors (CAR) in the treatment of hematological malignancies. However, the therapeutic efficacy of CAR-T lymphocytes against solid tumors, which represent the majority of tumors, is still insufficient. One of the reason…
(Only some records are available in English at this moment)
The therapies based on synthetic biology to modify T cell to express chimeric antigen receptor (CAR) have emerge as a revolutionary approach to treat hematological malignancies, and now are established as a treatment for relapse and/or refractory patients. However, the therapeutic efficacy of CAR-T cells is still low against solid tumors. The treatment of solid tumors with CAR-T cells is …
The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Although CAR-T cell therapy has demonstrated encouraging results with complete response rates of 70%-90% in patients with B cell malignancies, this new therapeutic modality is not yet fully mastered nor optimized. Some rec…
Inhibitory antibodies development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and decreased life quality. Approximately 5% of patients with hemophilia B and 20 to 30% of patients with severe hemophilia A, who use factor IX (FIX) and factor VIII (FVIII) replacement therapy, respectively, develop ant…
| 4 / 4 | Ongoing research grants |
| 12 / 8 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 52 / 27 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 2 / 2 | Completed scholarships abroad |
| 73 / 44 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID